| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/28/2006 | CA2612332A1 Bone morphogenetic protein formulations |
| 12/28/2006 | CA2612262A1 Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases |
| 12/28/2006 | CA2612233A1 Use of vegf for wound healing |
| 12/28/2006 | CA2612102A1 Methods of protecting against apoptosis using lipopeptides |
| 12/28/2006 | CA2611924A1 Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection |
| 12/28/2006 | CA2611491A1 Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules |
| 12/28/2006 | CA2610281A1 Therapeutic agent for cancer |
| 12/28/2006 | CA2609251A1 Pharmaceutical compositions and use thereof |
| 12/28/2006 | CA2609077A1 Lgi, lingo and p75ntr family members: novel modulators of neuronal growth |
| 12/28/2006 | CA2583345A1 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| 12/27/2006 | EP1736775A1 Novel ligand of g protein coupled receptor protein and use thereof |
| 12/27/2006 | EP1736547A1 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation |
| 12/27/2006 | EP1736545A2 Soluble zcytor 11 cytokine receptors |
| 12/27/2006 | EP1736544A1 Gm1 PROMOTER AND USE THEREOF |
| 12/27/2006 | EP1736541A1 Novel galectin 9 modification protein and use thereof |
| 12/27/2006 | EP1736173A1 Damaged tissue therapeutic agent and therapeutic method |
| 12/27/2006 | EP1736171A1 Antiobesity drug |
| 12/27/2006 | EP1736170A2 Agent for treating allergic or hypersensitivity condition |
| 12/27/2006 | EP1736169A1 Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment |
| 12/27/2006 | EP1736168A1 Protease inhibitor and preventives or remedies for diseases |
| 12/27/2006 | EP1736163A1 CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| 12/27/2006 | EP1736153A2 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) |
| 12/27/2006 | EP1736152A2 Physiologically stable compositions of butyric acid as well as butyric acid salts and derivatives for treating wounds |
| 12/27/2006 | EP1736136A1 Enzyme inhibiting spray skin barrier compositions |
| 12/27/2006 | EP1735468A2 Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer |
| 12/27/2006 | EP1735446A2 Therapeutic peptides |
| 12/27/2006 | EP1735445A2 Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| 12/27/2006 | EP1735443A2 RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 12/27/2006 | EP1735439A2 Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1 |
| 12/27/2006 | EP1735434A1 Method for modification of nmda receptors through inhibition of src |
| 12/27/2006 | EP1735433A2 Subtilase variants having altered immunogenicity |
| 12/27/2006 | EP1735344A1 Vaccine composition comprising a class ii cmh ligand coupled with an antigen, method for the preparation and the use thereof |
| 12/27/2006 | EP1735336A2 Omi pdz modulators |
| 12/27/2006 | EP1735335A1 Cell-killing peptide |
| 12/27/2006 | EP1735055A1 Method of reducing c-reactive protein using growth hormone secretagogues |
| 12/27/2006 | EP1735011A2 Method of modulating vascularization |
| 12/27/2006 | EP1735010A2 Methods, compositions, and preparations for delivery of immune response modifiers |
| 12/27/2006 | EP1735008A2 Tetanus toxin fusion protein for visualization of active synapses |
| 12/27/2006 | EP1734999A2 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure |
| 12/27/2006 | EP1734991A2 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases |
| 12/27/2006 | EP1734990A1 Use of corticotroph-derived glycoprotein hormone to treat liver steatosis |
| 12/27/2006 | EP1734989A1 Novel use of antisecretory factor |
| 12/27/2006 | EP1734988A2 Interferon-beta polymer conjugates |
| 12/27/2006 | EP1734987A2 Interferon-beta for anti-virus therapy for respiratory diseases |
| 12/27/2006 | EP1734986A1 Method for modulating appetite |
| 12/27/2006 | EP1734985A2 Methods for suppressing neovascularization using ephrinb2 |
| 12/27/2006 | EP1734984A2 Compositions and methods for topical diagnostic and therapeutic transport |
| 12/27/2006 | EP1734983A2 Modified annexin proteins and methods for preventing thrombosis |
| 12/27/2006 | EP1734982A2 Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling |
| 12/27/2006 | EP1734981A1 TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS |
| 12/27/2006 | EP1734980A1 Use of peptidic compounds for the prophylaxis and treatment of chronic headache |
| 12/27/2006 | EP1734979A2 Follicle stimulating hormone superagonists |
| 12/27/2006 | EP1734973A2 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase |
| 12/27/2006 | EP1734971A1 Polymer-based sustained release device |
| 12/27/2006 | EP1734938A1 Insulin highly respirable microparticles |
| 12/27/2006 | EP1734935A1 Poly (lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar |
| 12/27/2006 | EP1734827A2 Methods and compositions for treatment of diseases associated with aberrant microsatellite expansion |
| 12/27/2006 | EP1684789A4 Mammalian t1r3 sweet taste receptors |
| 12/27/2006 | EP1539964B1 Collectin-complement activating protein chimeras |
| 12/27/2006 | EP1480961B1 Glutaminyl based dpiv inhibitors |
| 12/27/2006 | EP1440159B1 Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma |
| 12/27/2006 | EP1427423B1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| 12/27/2006 | EP1418180B1 Chimeric chains that code for proteins that induce effects directed against viruses |
| 12/27/2006 | EP1404704B1 Bridged bicyclic serine protease inhibitors |
| 12/27/2006 | EP1397380B1 Multiple antigenic peptide displaying multiple copies of an epitope of a plaque-forming polypeptide and methods of using same |
| 12/27/2006 | EP1379515B1 Lipid lowering biphenylcarboxamides |
| 12/27/2006 | EP1373500B1 Gene involved in v(d)j recombination and/or dna repair |
| 12/27/2006 | EP1358209B1 Crystallization of igf-1 |
| 12/27/2006 | EP1339422B1 Histaminase of vegetable origin for use in the treatment of allergic and septic shock and of allergic asthma |
| 12/27/2006 | EP1332372B1 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression |
| 12/27/2006 | EP1328621B1 13245, a novel human myotonic dystrophy type protein kinase and uses therefor |
| 12/27/2006 | EP1326974B1 Methods of using a human il-17-related polypeptide to treat disease |
| 12/27/2006 | EP1303602B1 Soluble zalpha11 cytokine receptors |
| 12/27/2006 | EP1297147B1 Compositions for the diagnosis and treatment of herpes simplex virus infection |
| 12/27/2006 | EP1225870B1 Composition and method of cancer antigen immunotherapy |
| 12/27/2006 | EP1183367B1 Cytotoxic t-cell epitope of the papillomavirus l1-protein and use thereof in diagnostics and therapy |
| 12/27/2006 | EP1117437B1 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke |
| 12/27/2006 | EP1105505B1 Compound and method for the prevention and/or the treatment of allergy |
| 12/27/2006 | EP1103560B1 Novel thiazolidine derivatives |
| 12/27/2006 | EP1073739B1 Cd40-interacting and traf-interacting proteins |
| 12/27/2006 | EP1034273B1 Histamine and serotonin binding molecules |
| 12/27/2006 | EP1028742B1 Apo b, annexin v and tubulin : medical, diagnostic and purification uses for hcv |
| 12/27/2006 | EP1007549B1 Compositions and methods for highly efficient transfection |
| 12/27/2006 | EP0998495B1 Amyloid beta protein (globular assembly and uses thereof) |
| 12/27/2006 | EP0973804B1 Anti-vegf antibodies |
| 12/27/2006 | EP0918458B1 Antimicrobial treatment for herpes simplex virus and other infectious diseases |
| 12/27/2006 | EP0817797B1 Glycopeptide antibiotic derivatives |
| 12/27/2006 | EP0783891B1 Interferon-beta for bone diseases |
| 12/27/2006 | EP0638123B1 Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form |
| 12/27/2006 | CN1886511A Chimeric type 5/type 11 or type 35 adenovirus vector for preventing infection with antihuman immunodeficiency virus |
| 12/27/2006 | CN1886423A Glycoisoforms of adiponectin and uses thereof |
| 12/27/2006 | CN1886422A A method of modulating cell survival, differentiation and/or synaptic plasticity |
| 12/27/2006 | CN1886421A Hemiasterlin derivatives and uses thereof |
| 12/27/2006 | CN1886155A Isolated mammalian membrane protein genes and related reagents |
| 12/27/2006 | CN1886154A Clostridium botulinum C3 exotransferase compositions and methods for treating tumour spreading |
| 12/27/2006 | CN1886153A Excipients in drug delivery vehicles |
| 12/27/2006 | CN1886152A Minimization of drug oxidation in drug irradiated excipients formulations |
| 12/27/2006 | CN1886151A Pharmaceutical formulations for the sustained release of oneor more active principles and applications thereof, such as therapeutic applications |
| 12/27/2006 | CN1886150A Fibroblast-mobilizing agent containing g-csf and wound remedy |
| 12/27/2006 | CN1886149A VEGF-C or VEGF-D materials and methods for stimulation of neural stem cells |